SG/CALL/EDWARDS LIFESCIENCES/80/0.1/20.12.24 | Delayed Deutsche Boerse AG 20:36:38 24/06/2024 BST | ||
| 1.6 EUR | -1.84% |
|
| Current month | +13.48% | ||
| 1 month | +3.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 1.6 | -1.84% |
| 21/06/24 | 1.63 | +3.16% |
| 20/06/24 | 1.58 | +10.49% |
| 19/06/24 | 1.43 | -5.30% |
| 18/06/24 | 1.51 | +7.09% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 08:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2MAP |
| ISIN | DE000SU2MAP2 |
| Date issued | 22/11/2023 |
| Strike | 80 $ |
| Maturity | 20/12/2024 (179 Days) |
| Parity | 10 : 1 |
| Emission price | 0.96 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.41 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.01 € |
| Spread % | 0.63% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.17
USD
Average target price
96.05
USD
Spread / Average Target
+6.52%
- Stock Market
- Warrants
- Warrant
